Sunday, March 30, 2025 3:02:29 AM
At the stage were at with approval it would be a let down for MHRA to approve Dcvax to be manufactured in clean rooms only.
And if you think about it Britain and MHRA would have never backed this new treatment if it was just another cell therapy treatment that was to expensive to provide to the population.
Britain is looking for a win here.. And thats being able to offer treatments to paying customers at 250 thou usd while subsidizing the cost that there citizens pay.
Nwbo and the British government have one chance at this announcement of approval
Heres my suggestion for the joint PR
This new cutting edge cancer treatment that Mhra has supported over the years is going to be approved at a suggested cost of 150 thou USD to our citizens. The cost to non citizens will be 250 thou
British citizens will be prioritized of course.
And if you think about it Britain and MHRA would have never backed this new treatment if it was just another cell therapy treatment that was to expensive to provide to the population.
Britain is looking for a win here.. And thats being able to offer treatments to paying customers at 250 thou usd while subsidizing the cost that there citizens pay.
Nwbo and the British government have one chance at this announcement of approval
Heres my suggestion for the joint PR
This new cutting edge cancer treatment that Mhra has supported over the years is going to be approved at a suggested cost of 150 thou USD to our citizens. The cost to non citizens will be 250 thou
British citizens will be prioritized of course.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
